A search for possible correlations of CD30 + SEVs quantity in plasma with other clinically relevant characteristics of cHL patients (B symptoms, blood count, and metabolic activity of residual tumor mass) will estimate the potency of the proposed test as a method for therapy effect monitoring and treatment tailoring. This evidence concerns the gene TNFRSF8 and neoplasm.